首页> 外文期刊>Blood coagulation & fibrinolysis: an international journal in haemostasis and thrombosis >Antithrombin Cambridge II(A384S) mutation frequency and antithrombin activity levels in 120 of deep venous thrombosis and 150 of cerebral infarction patients in a single center in Southern China.
【24h】

Antithrombin Cambridge II(A384S) mutation frequency and antithrombin activity levels in 120 of deep venous thrombosis and 150 of cerebral infarction patients in a single center in Southern China.

机译:中国南方一个中心地区120名深静脉血栓形成和150名脑梗死患者的抗凝血酶Cambridge II(A384S)突变频率和抗凝血酶活性水平。

获取原文
获取原文并翻译 | 示例
           

摘要

Antithrombin Cambridge II(A384S) mutation shows a relatively high frequency in western population. Some studies suggest that the mutation is an independent genetic risk factor both for deep vein thrombosis (DVT) and for arterial thrombosis, but whether the mutation has racial difference or has a general significance for thrombophilia remains unclear. In this study we performed an analysis of the prevalence of the mutation in Chinese southern population; Also, the antithrombin activity levels were evaluated in each investigated individual. The studies included 120 patients with DVT, 150 patients with cerebral infarction, and 110 controls. The mutation was detected using polymerase chain reaction/PvuII restrictive fragment length polymorphism procedures. Antithrombin activity assay was done using chromogenic substrate method. The results showed that no antithrombin Cambridge II mutation was detected in all three groups (DVT, cerebral infarction and controls), the incidence was 0/380. Plasma antithrombin activity was 91.37% +/- 16.15% in the DVT patients and 102.68% +/- 13.10% in the controls; the antithrombin activity was significantly reduced in the DVT group (P < 0.0001). In DVT patients, eight cases were identified as primary antithrombin deficiency, accounting for an incidence of 6.7%. No significant difference was found for antithrombin activity between cerebral infarction group and controls. These results suggest that antithrombin Cambridge II mutation has a racial difference, and may not be a valuable risk factor of thrombophilia in Asian population, and antithrombin deficiency remains a major genetic risk factor for DVT patients in China.
机译:抗凝血酶Cambridge II(A384S)突变在西方人群中显示相对较高的频率。一些研究表明,该突变是深静脉血栓形成(DVT)和动脉血栓形成的独立遗传危险因素,但尚不清楚该突变是否具有种族差异或对血友病具有普遍意义。在这项研究中,我们对中国南方人口中突变的发生率进行了分析。同样,在每个被调查的个体中评估抗凝血酶活性水平。该研究包括120例DVT患者,150例脑梗塞患者和110例对照。使用聚合酶链反应/ PvuII限制性片段长度多态性程序检测突变。使用生色底物方法进行抗凝血酶活性测定。结果表明,在所有三个组(DVT,脑梗死和对照组)中均未检测到抗凝血酶Cambridge II突变,发生率为0/380。 DVT患者的血浆抗凝血酶活性为91.37%+/- 16.15%,对照组为102.68%+/- 13.10%; DVT组的抗凝血酶活性显着降低(P <0.0001)。在DVT患者中,有8例被确定为原发性抗凝血酶缺乏症,占6.7%的发生率。在脑梗死组和对照组之间抗凝血酶活性没有发现显着差异。这些结果表明抗凝血酶Cambridge II突变具有种族差异,并且可能不是亚洲人群血栓形成的有价值的危险因素,而抗凝血酶缺乏症仍然是中国DVT患者的主要遗传危险因素。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号